33% CAGR 'til 2020 for global mHealth market

The global mobile health market is expected to grow at a compound annual growth rate of 33.5 percent between 2015 and 2020, according to Allied Market Research.

The market is currently valued at $10.5 billion in 2014.

Allied predicts that blood pressure monitors will lead the global mHealth device market, followed by blood glucose monitors and cardiac monitors. Collectively, the three devices will represent 71 percent of the market share thanks to increased affordability of mobile compatible devices, integration of innovative technologies in monitoring devices and the increasing prevalence of lifestyle diseases such as diabetes, stroke and COPD.

The blood glucose meter device category is projected to be the fastest growing segment with a compound annual growth rate of 41 percent during the forecast period. The cardiovascular and diabetes mHealth app market “remains the most lucrative market segment for manufacturers.” 

North America will continue to geographically dominate the mHealth market over the next five years, with the United States leading throughout the forecast period. Asia-Pacific is poised to be the fastest-growing mHealth market, however, with a compound annual growth rate of 35.9 percent. The market outlook for developing economies is “looking favorable and strong owing to the increasing awareness of chronic diseases, favorable government regulations and increased healthcare expenditure,” according to Allied.

“The advanced mobile and wireless technologies have transformed the face of healthcare services across the globe and are rendering the growth of mHealth markets,” the report reads. “Moreover, the continued growth in coverage of mobile cellular networks, rapid advances in mobile technologies and applications, increasing lifestyle diseases and growing awareness among patient population in emerging economies, are some of the key factors fostering growth of the global mHealth market.”

 

Beth Walsh,

Editor

Editor Beth earned a bachelor’s degree in journalism and master’s in health communication. She has worked in hospital, academic and publishing settings over the past 20 years. Beth joined TriMed in 2005, as editor of CMIO and Clinical Innovation + Technology. When not covering all things related to health IT, she spends time with her husband and three children.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.